chemotherapy does not exceed 5-10%. Advanced age (median, 65 years), renal function impairment and hematoThis report summarizes 2 years experience in perpoietic stem cell compromise due to prolonged alkylating forming 336 autotransplant procedures in 251 consecuagent therapy have delayed evaluation of high-dose chemotive patients with multiple myeloma, using high-dose therapy in MM, an approach that has proven to be successmelphalan at 200 mg/m 2 in the context of a tandem ful in the management of lymphomas. 2 Pilot studies in the transplant program. A total of 91 patients received 118 early 1980s revealed that drug-resistance in advanced MM transplants as outpatients while the remaining 160 could be overcome by dose-escalation of alkylating patients received 218 transplants as inpatients. Outagents. 3, 4 As a result, numerous clinical trials have patients were more often younger, with better stem cell employed autologous stem cells, as well as colony-stimulatproducts, normal serum albumin and ␤-2-microglobuing factors, to support myeloablative therapy for MM. 5-9 A lin levels as well as chemotherapy-sensitive disease comrandomized clinical trial by French investigators has shown pared to inpatients. There were no differences in hemaautotransplant to be superior to standard chemotherapy in topoietic recovery and non-hematologic toxicities the management of newly diagnosed symptomatic myeloma between outpatient and inpatient transplant recipients.
Summary:
chemotherapy does not exceed 5-10%. Advanced age (median, 65 years), renal function impairment and hematoThis report summarizes 2 years experience in perpoietic stem cell compromise due to prolonged alkylating forming 336 autotransplant procedures in 251 consecuagent therapy have delayed evaluation of high-dose chemotive patients with multiple myeloma, using high-dose therapy in MM, an approach that has proven to be successmelphalan at 200 mg/m 2 in the context of a tandem ful in the management of lymphomas. 2 Pilot studies in the transplant program. A total of 91 patients received 118 early 1980s revealed that drug-resistance in advanced MM transplants as outpatients while the remaining 160 could be overcome by dose-escalation of alkylating patients received 218 transplants as inpatients. Outagents. 3, 4 As a result, numerous clinical trials have patients were more often younger, with better stem cell employed autologous stem cells, as well as colony-stimulatproducts, normal serum albumin and ␤-2-microglobuing factors, to support myeloablative therapy for MM. [5] [6] [7] [8] [9] A lin levels as well as chemotherapy-sensitive disease comrandomized clinical trial by French investigators has shown pared to inpatients. There were no differences in hemaautotransplant to be superior to standard chemotherapy in topoietic recovery and non-hematologic toxicities the management of newly diagnosed symptomatic myeloma between outpatient and inpatient transplant recipients.
patients. 10 In the interest of offering this promising treatPost-transplant febrile neutropenia and most other ment strategy to a larger MM patient population, outpatient post-transplant toxicities were managed successfully in transplants were initiated at our institution and their safety, an ambulatory setting. Although liberal criteria were efficacy, and cost-effectiveness were examined. developed for hospitalization of outpatients, including High-dose melphalan was chosen as cytoreductive regiclinical parameters as well as patient desire and men because of its relative lack of extra-medullary toxicity, physician/nurse judgment, only 21% of outpatients even at 200 mg/m 2 . 11, 12 The initiation of outpatient transrequired admission after transplantation. Median hosplants required a high degree of proficiency on the part of pital stay for these outpatients was 9 days, while inpathe transplant team and an adequate outpatient nursing and tients were hospitalized for a median of 15 days (P ‫؍‬ pharmacy infrastructure to ensure continuity of care, even 0.0001). After adjusting for differences in disease and at weekends. Because only two outpatient autotransplant host features, our study showed outpatient management procedures could be accommodated per week, patient perresulted in significant financial savings due to lower formance status and preference, as well as third-party pharmacy (42%), hospitalization (50%) and insurance payments influenced whether or not a patient was pathology/laboratory charges (36%). We conclude that accepted for outpatient transplantation. outpatient transplants should facilitate access to myeThis report summarizes our experience over 2 years in loablative therapy, thereby improving complete performing 336 autotransplants in 251 consecutive MM remission rates and survival of myeloma patients.
patients, using high-dose melphalan in the context of a tanKeywords: multiple myeloma; high-dose melphalan; outdem transplant program; 91 patients received 118 transpatient transplant plants as outpatients, while the remaining 160 patients received 218 transplants as inpatients. Patient characteristics, clinical outcomes, and charges were compared Multiple myeloma (MM) remains a uniformly fatal B cell between outpatient and inpatient procedures. Results indineoplasm due to the marked drug-resistance of tumor cells cate that safe outpatient management is feasible in almost to standard chemotherapy. 1 Using stringent criteria, the 80% of patients, resulting in reduced expenditure. incidence of complete remission (CR) following standard Prophylactic and therapeutic antibiotics participated in protocols involving high-dose cyclophosphamide for peripheral blood stem cell mobilization Ciprofloxacin 1 g, penicillin V potassium 1 g and mycelex (PBSC) with the intent to perform tandem autotransplants 50 mg per day (5-10 mg troches) were administered with high-dose melphalan within 6 months. Patients were prophylactically. In cases of penicillin allergy, erythromyeligible up to age 70 years (one exception, age 71) provided cin 1 g or cephalexin 1 g was substituted.
In the presence their organ functions were adequate, as determined by carof severe mucositis with odynophagia, ciprofloxacin 400 diac left ventricular ejection fraction Ͼ50%, forced vital mg twice a day was administered i.v., along with penicillincapacity (FVC), and CO diffusion capacity Ͼ50%, liver G 2 million units four times a day (inpatients) or vancomyfunction abnormalities less than twice the upper range of cin 1 g daily (outpatients), and oral fluconazole 200 mg normal, and creatinine р3 mg/dl. Minimum eligibility cridaily (all patients). teria for outpatients included ambulatory status (Zubrod All patients received GM-CSF 250 g/m 2 starting on day Ͻ2), adequate cryopreserved PBSCs, motivation for self-+1 until neutrophils exceeded 2 × 10 9 /l for 2 consecutive care, and accompaniment by a responsible adult during the days. G-CSF (5 g/kg bw) was substituted in patients who entire transplant course.
were intolerant to GM-CSF. Hospitalized patients were At the time of initial diagnosis, 49% of patients had nursed in private HEPA-filtered positive airflow rooms in Durie-Salmon stage III and 46% had received more than the transplant unit; outpatients were provided with portable 1 year of standard chemotherapy. Three patients with HEPA filters for their hotel rooms. creatinine Ͼ3 mg/dl participated, including one patient Daily blood cultures were obtained from outpatients duron hemodialysis.
ing neutropenia (Ͻ0.5 × 10 9 /l). Outpatients were provided with one infusor each of vancomycin 1 g and ceftazidime 2 g (stable for 7 days) and these were self-administered if Stem cell procurement their temperature spiked to у38.3°C during non-clinic hours; the physician on-call was notified in such cases. For PBSC mobilization, patients received cyclophosphamSelf-administration of vancomycin 1 g and ceftazidime 2 g ide 6 g/m 2 , along with a continuous infusion of MESNA was continued every 12 h. Vancomycin dosing was 4.5 g/m 2 , over 24 h. 11 On day 2, granulocyte-macrophage adjusted according to peak and trough levels. Inpatients colony-stimulating factor (GM-CSF) 250 g/m 2 was developing febrile neutropenia received the same antibiotic administered subcutaneously each day until stem cell apherregimen, although ceftazidime was administered every 8 h esis was completed or total leukocytes exceeded 30 × 10 9 /l. in these patients. Granulocyte colony-stimulating factor (G-CSF) was substituted for GM-CSF in cases of serious cytokine-associated toxicity. Apheresis was begun when leukocytes exceeded
Criteria for hospital admission of outpatients 0.5 × 10 9 /l and platelets approached 50 × 10 9 /l, as described Indications for hospitalization included intractable nausea, previously.
11,12 A minimum of 6 × 10 8 mononuclear cells vomiting or diarrhea requiring parenteral alimentation, per kilogram of body weight (MNC/kg bw) was collected and/or severe mucositis necessitating administration of narfrom patients with maximum CD34 у2%, or at least cotic analgesics. Likewise, capillary leak syndrome from 10 × 10 8 MNC/kg bw from patients whose maximum CD34 cytokine toxicity with weight gain over 5 kg, hemodynamic level was Ͻ2%. CD34 was determined daily for at least instability, cardiac or respiratory distress, pneumonia, or the first 3 days of PBSC collection, as well as on infused documented bacteremia (except with coagulase-negative PBSCs, as reported previously. 12 Patients with marrow staphylococcus) were additional criteria used for hospitalizplasmacytosis р30% also underwent bone marrow harvest.
ation of these patients. In addition, patients were admitted at their request, or if it was considered to be in their best interest in the judgment of the transplant physician/nursing High-dose chemotherapy team, based on a decrease in performance status during the The preparative regimen for the first autotransplant concourse of the treatment. A bed in the transplant unit was sisted of melphalan 200 mg/m 2 administered in doses of always made available on a priority basis for persons 100 mg/m 2 i.v. over 30 min on days −3 and −2. PBSCs, undergoing outpatient transplants. with or without autologous marrow, were infused on day 0. Patients who responded to the first transplant received Ancillary outpatient management and support a second transplant within 3-6 months, using an identical preparative regimen. In the absence of sustained PR by the A responsible adult companion was required to be available during the entire transplant course. A dedicated and experitime of the second transplant, the myeloablative regimen Characteristics of both groups are shown in Table 1 . As shown, outpatients were associated with lower frequencies USA), or i.v. narcotics. The clinic was open 7 days a week from 8 am to 5 pm; after hours, patients had access to a of older age (у60 years), hypoalbuminemia (р3.5 g/dl), prior chemotherapy resistance, pre-transplant ␤ 2 transplant physician for medical emergencies and to outpatient transplant nurses for help with malfunctioning microglobulin elevation (Ͻ2.5 m/l), and low maximum CD34 percent (у2%) in the apheresis product (all P Ͻ pumps or infusors.
0.05). Within 15 days post-transplant, more than 90% of Response criteria patients in both groups reached granulocyte counts exceeding 0.5 × 10 9 /l, and 70% had platelet counts that Complete remission (CR) was defined as the absence of exceeded 50 × 10 9 /l. Thus, both groups had identical monoclonal gammopathy in serum and urine by immunoengraftment kinetics. No intergroup differences in hematolfixation electrophoresis (IFE) and less than 1% monoclonal ogic recovery were observed after the first or second transplasma cells in the bone marrow aspirate and biopsy. To plants (data not shown); rather, the speed of recovery was be classified as a partial remission (PR), there had to be related to the number of CD34 cells/kg bw infused. With у75% decrease in serum M component, у90% decrease CD34 у2 × 10 6 /kg, median durations to granulocytes in Bence-Jones proteinuria, and Ͻ5% monoclonal marrow Ͼ0.5 × 10 9 /l and to platelets Ͼ50 × 10 9 /l were 10 and 12 plasmacytosis on flow cytometry of DNA and cytoplasmic days, respectively, which were significantly shorter than the light chain. 13 No new lytic lesions or soft tissue plasma-12 and 49 days observed in patients receiving less than cytoma lesions could appear. Development of compression 2 × 10 6 CD34 cells/kg bw (P Ͻ 0.001). fractures was not necessarily an indication of disease proToxicities (the frequencies of febrile neutropenia, stomagression. These response criteria had to exist for at least titis grade Ͼ2, and documented bacteremia or pneumonia 2 months.
(P Ͼ 0.1 for each)), were similar between the two groups. Also similar were use of i.v. antibiotics and hyperalimentation (Table 2) . Platelets were administered more liberally Analysis of charges to outpatients: only 3% of outpatient procedures required no platelet transfusions compared to 8% of inpatient proCharges by providers were used as a proxy of treatment procedure cost. Hospital charges for patients were obtained cedures (P Ͻ 0.04). However, fewer outpatient procedures (57%) required packed red cell transfusions compared to from the UAMS University Hospital Office of Financial Administration and divided into four subcategories: pharinpatient procedures (69%, P = 0.02). Of the 118 outpatient transplants, 79% (93 in 69 patients) macy, pathology-laboratory, room and board, and miscellaneous. Physician charges were obtained from the UAMS never required admission (Figure 1 ). Hospital admission typically occurred at the nadir of neutropenia, a median of Medical College Physicians' Group. Four adjustments were made to charges: (1) all charges were adjusted for inflation eight days post-transplantation (range, 4-21 days) ( Figure  1 ). The median duration of hospital stay was only 9 days and expressed in second quarter 1994 dollars (medical inflation for 1994 was assumed to be 7% 14 ); (2) $100 was (range, 4-21 days) among the 25 outpatient procedures requiring it, which was significantly shorter than the averadded for each outpatient day to cover the hotel room charges ($40/day) and meals for the patient and companion age 15-day hospitalization stay (range, 3-115 days) for the 218 inpatient transplants (Figure 2 ). Frequency and dur-($60/day); (these charges were already included in hospital charges to inpatients); (3) the estimated cost of the comation of hospitalization among the 27 patients receiving both transplants in the outpatient setting were virtually panion's time was added to the outpatient transplant charges as a miscellaneous expense ($100/day, based on identical. Admission to the intensive care unit was required in 13 of 218 inpatient procedures compared to two of 118 lost earnings at an hourly wage of $12.50); and (4) inpatient pharmacy charges were discounted so that the unit prices outpatient procedures (P = 0.07).
Reasons for hospitalization among outpatients included were the same between inpatient and outpatient pharmacies.
Multiple regression analyses were employed to assess intractable nausea, vomiting, or diarrhea requiring parenteral alimentation and/or severe mucositis necessitating charge differences between inpatient and outpatient transplants, accounting for differences in disease and patient administration of narcotic analgesics (28%); bacteremia or pneumonia (28%); febrile neutropenia and gastrointestinal characteristics between in-and outpatient groups. Adjusted average charges were computed for each charge category toxicity (24%); or persistent fever for more than 3 days (12%). Two patients who received outpatient autotransin both patient groups. tiple regression analysis was employed to determine the key factors associated with savings, taking into account inpatient and outpatient transplant procedures and other factors such as patient age, gender, prior response to therapy, time from diagnosis to first transplant, immunoglobulin isotype, disease stage, number of CD34 + cells infused as well as serum levels of creatinine, lactate dehydrogenase, ␤ 2 microglobulin and albumin. Differences between inpatients and outpatients in adjusted average charges were computed for each charge category (Table 3) . Transplant in the outpatient setting was the only significant variable associated outpatients than for inpatients. Outpatient savings were realized mainly through lower hospitalization charges (50% of overall savings). Outpatients also realized savings of 42% on pharmacy charges and 37% on pathology/ Table 3 Inpatient vs outpatient differences in charges laboratory charges. Outpatients incurred higher miscelplant physician for medical emergencies and to nurses for help with malfunctioning pumps or infusors through a laneous charges ($3979), which reflected expenses borne by patients' companions due to lost earnings. Physician dependable answering service. Post-transplant febrile neutropenia was successfully charges were similar in both groups.
Cost analysis was also performed in the subgroup of managed in the majority of outpatients in our study through prompt self-administration of antibiotics via infusors conpatients 60 years or younger with normal serum albumin levels and MM previously responsive to standard therapy nected to central venous catheters, lessening or eliminating the need for emergency hospital admissions. In contrast, (key features in which inpatient and outpatient groups differed, see Table 1 ). Eighty-nine inpatient and 90 outpatient Peters et al 16 admitted febrile neutropenic patients to the hospital for evaluation and initiation of parenteral antitransplant procedures met these criteria. These two groups were then matched for age (р60 years), serum albumin biotics. In the Peters study, patients were discharged after stabilization of neutropenia on the condition that parenteral (у3.5 g/dl), ␤ 2 microglobulin (р2.5 mg/l), and quantity of CD34 cells infused (у2 × 10 6 CD34 + cells/kg) (P Ͼ 0.2). antibiotics were administered in the clinic once a day. The frequency of positive blood cultures was similar for In this subgroup analysis, outpatient transplantation showed a savings of $9412, due to lower pharmacy charges outpatients and inpatients in our study, suggesting that blood cultures need only be obtained at the time of febrile ($5444), hospital bed ($6863), and pathology/clinical laboratory service charges ($3163). As with the entire neutropenic episodes. Although outpatients received ceftazidime less frequently (twice a day) than inpatients (three population, the charges in the miscellaneous category were higher for 'outpatients' ($5669).
times a day), outcomes were not adversely affected, possibly because severely ill patients with documented sepsis were managed as inpatients, and because the incidence of gram-negative sepsis was less than 5%. No outpatients Discussion required emergency admission because of hypotension or septic shock, underscoring the safety of our approach. A randomized clinical trial conducted by French investigators indicated an improved prognosis over conventional Cost savings at a single center for inpatient autotransplantation in lymphoma and Hodgkin's disease were chemotherapy in patients with multiple myeloma after autotransplant-supported myeloablative therapy with melphalan reported by Bennett et al 18 and were attributed to patient selection, more rapid hematologic recovery due to the 140 mg/m 2 plus TBI 800 cGy. 15 Similar results have been suggested by the Royal Marsden group 7 (single transplant administration of growth factors and mobilized PBSCs, and transplant team proficiency. By providing equivalent care with melphalan 200 mg/m 2 ) and by ourselves. 11 A greater demand for high-dose therapy with transplant support for for outpatients and inpatients, we report significant savings in charges for the outpatient procedure. Because cost distrithe treatment of MM can, therefore, be anticipated. This report demonstrates that outpatient autotransplants can be bution is usually skewed, some transformation, such as logarithm transformation, is usually required for a cost comperformed at considerable savings in health care expenditure. For logistic reasons, only two outpatient transplants parison. In a separate analysis, therefore, we performed a logarithm transformation of charges and used the smearing could be performed per week. Hence, several patients receiving inpatient transplants were in fact outpatient transre-transformation technique suggested by Duan 19 to make a consistent estimate of charges in the untransformed scale. plant candidates. In fact, 34 patients receiving inpatient transplants (15%) were discharged within 3 days after
The results showed a total average charge of $49 023 for the inpatient cases and $36 569 for the outpatient cases, transplant.
Our treatment regimen for MM may be more suitable for resulting in a difference of $12 454. These results are not substantially different from those without the transformoutpatient management because of the ease of administration of high-dose melphalan, which shows a lack of ation because our charge distribution is not highly skewed. Our patient selection criteria for outpatient management excessive extramedullary toxicity, including nausea and vomiting. The duration of cytopenia does not exceed 10 and liberal criteria for hospitalization of these patients has resulted in safe conduct of outpatient transplants. Adequate days after rescue with chemotherapy-mobilized stem cells and hematopoietic growth factor. Our study differs from outpatient nursing and pharmacy infrastructure provided continuity of care for these patients 7 days a week. Most that of Peters et al, 16 in that all of their patients were hospitalized initially for the administration of high-dose therapy of the post-transplant toxicities (eg febrile neutropenia, mucositis) and required interventions (eg parenteral and stem cell infusion and subsequently managed on an outpatient basis. Meisenberg et al 17 used a similar strategy, nutritional support and pain management) were handled successfully in the ambulatory care setting. Wider applihospitalizing patients initially to administer chemotherapy for the first 96 patients and subsequently offering total outcation of these outpatient management techniques will help in overall cost containment and make autotransplants more patient chemotherapy and transplants in 48 additional patients. They have shown that outpatient management is readily accessible to patients with MM. safe and resulted in significantly reduced hospital stays for a variety of malignancies with different disease-specific chemotherapy regimens.
